CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare†or the "Company†) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares†and the holders of the Common Shares, the "Shareholders†) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly "Xeno†) a non- profit biotechnology company, b. ...

Group 1 - Gilead Sciences has agreed to acquire Repare Therapeutics' RP-3467, a polymerase theta ATPase inhibitor, for a total consideration of up to $30 million, which includes a $25 million upfront payment and up to an additional $5 million based on technology transfer activities [1] - The acquisition is expected to enhance Repare's cash reserves, leading to an estimated shareholder payment of approximately $2.20 per common share upon closing the arrangement transaction [3] - Repare's CEO, Steve Forte, highlighted the significance of this transaction, marking it as the third major portfolio transaction for Repare in the year, and emphasized the potential of RP-3467 as a leading Polθ ATPase inhibitor linked to breast cancer gene mutations [4] Group 2 - On November 14, 2025, Repare announced a definitive arrangement agreement with XenoTherapeutics for the purchase of all its issued and outstanding common shares, with shareholder payments based on the company's closing cash balance after expenses and liabilities [2] - In May 2025, Repare entered into an out-licensing agreement with DCx Biotherapeutics for discovery platforms and intellectual property, indicating ongoing strategic partnerships in the biotechnology sector [5]

Core Viewpoint - Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences to acquire the experimental cancer therapy RP-3467, with a total transaction value of up to $30 million [1][3]. Group 1: Transaction Details - The agreement stipulates that Repare will receive up to $25 million in upfront payments from Gilead, with an additional potential of up to $5 million in subsequent payments upon completion of specific technology transfer-related matters [3]. - This upfront payment is expected to impact Repare's net cash position at the time of the merger completion [3]. Group 2: Impact on Stock Valuation - Following the announcement, the cash consideration per share for Repare in its previously agreed merger with XenoTherapeutics will increase to approximately $2.20, up from the prior offer of $1.82 per share [3]. Group 3: Clinical Development - Repare is advancing the POLAR Phase I clinical trial for RP-3467, assessing the safety and pharmacokinetic characteristics of the candidate drug when used in combination with the already marketed cancer drug olaparib [3]. - Olaparib is co-marketed by AstraZeneca and Merck under the brand name Lynparza [3].

Core Viewpoint - Repare Therapeutics has announced an asset purchase agreement with Gilead Sciences to acquire the experimental cancer therapy RP-3467, with a total transaction value of up to $30 million [1] Group 1: Transaction Details - The agreement includes a maximum upfront payment of $25 million from Gilead to Repare, with an additional potential payment of up to $5 million upon completion of specific technology transfer-related matters [1] - This upfront payment will impact Repare's net cash position at the time of the merger completion, increasing the cash consideration per share to approximately $2.20, up from the previously agreed $1.82 per share with XenoTherapeutics [1] Group 2: Clinical Development - Repare is advancing the POLAR Phase I clinical trial for RP-3467, assessing the safety and pharmacokinetic characteristics of the candidate drug in combination with olaparib across various tumors [1] - Olaparib is an already marketed cancer drug co-commercialized by AstraZeneca and Merck, known by the brand name Lynparza [1]

Core Viewpoint - Repare Therapeutics has announced an asset purchase agreement with Gilead Sciences to acquire the experimental cancer therapy RP-3467, with a total transaction value of up to $30 million [1] Group 1: Transaction Details - The agreement includes a maximum upfront payment of $25 million from Gilead to Repare, with an additional potential payment of up to $5 million upon completion of specific technology transfer-related matters [1] - This upfront payment is expected to impact Repare's net cash position upon the completion of the acquisition [1] Group 2: Impact on Stock Valuation - Following the announcement, the cash consideration per share for Repare in its previously agreed acquisition with XenoTherapeutics will increase to approximately $2.20, up from the prior offer of $1.82 per share [1] Group 3: Clinical Development - Repare is advancing the POLAR Phase I clinical trial for RP-3467, which evaluates the safety and pharmacokinetic characteristics of the candidate drug in combination with olaparib across various tumors [1] - Olaparib is an already marketed cancer drug co-commercialized by AstraZeneca and Merck, known by the brand name Lynparza [1]

Core Viewpoint - Repare Therapeutics has announced an asset purchase agreement with Gilead Sciences to acquire the experimental cancer therapy RP-3467, with a total transaction value of up to $30 million [1] Group 1: Transaction Details - The agreement includes a prepayment of up to $25 million from Gilead to Repare, with an additional potential payment of up to $5 million upon completion of specific technology transfer tasks [1] - This prepayment is expected to impact Repare's net cash position upon the completion of the acquisition [1] Group 2: Impact on Stock Valuation - Following the agreement, the cash consideration per share for Repare in its previously announced acquisition by XenoTherapeutics will increase to approximately $2.20, up from the initial offer of $1.82 per share [1] Group 3: Clinical Development - Repare is advancing the POLAR I phase clinical trial for RP-3467, which evaluates the safety and pharmacokinetic characteristics of the candidate drug in combination with olaparib across various tumors [1] - Olaparib is an already marketed cancer drug co-commercialized by AstraZeneca and Merck, known by the brand name Lynparza [1]

Group 1: Canadian Market Overview - Canadian stocks are expected to open muted ahead of Christmas, with an early closure at 1:00 PM today and a complete closure on Christmas and Boxing Day [1] - The S&P/TSX composite Index closed at 32,058.73, down 58.63 points or 0.18 percent [1] - The Canadian dollar strengthened against major currencies, reaching a 5-month high of 1.3673 against the U.S. dollar and a nearly 2-week high of 1.6123 against the euro [2] Group 2: Corporate Developments - Repare Therapeutics Inc. has reached an agreement with Gilead Sciences, Inc. to transfer its Pol? ATPase inhibitor, RP-3467, in a deal valued at up to $30 million [2] Group 3: European Market Overview - European shares are trading broadly higher, with the CAC 40 Index up 8.59 points or 0.11 percent, the German DAX up 56.09 points or 0.23 percent, and the Swiss Market Index gaining 79.14 points or 0.60 percent [3] - The Euro Stoxx 50 Index, which includes 50 blue chip stocks across the euro area, is up 5.06 points or 0.088 percent [3] Group 4: Asian Market Overview - Asian shares finished mostly up, with the Shanghai Composite gaining 20.97 points or 0.53%, closing at 3,940.95 [4]

Core Viewpoint - Repare Therapeutics Inc. has entered into an agreement with Gilead Sciences, Inc. to transfer its Pol? ATPase inhibitor, RP-3467, valued at up to $30 million, leading to a significant increase in the company's share price by over 20% in pre-market trading [1]. Group 1: Financial Details - The agreement includes a $25 million upfront payment and an additional $5 million contingent upon the completion of specified transfer activities [1]. - Following the Gilead agreement, Repare expects shareholders to receive approximately $2.20 per share, up from a previous expectation due to the increased cash balance [3]. - Repare's shares closed at $2.17, reflecting a decrease of 2.25% prior to the announcement [3]. Group 2: Product Development - RP-3467 is currently undergoing evaluation in a Phase 1 study as both a monotherapy and in combination with olaparib for various cancer types, including epithelial ovarian cancer, breast cancer, prostate cancer, and pancreatic adenocarcinoma [2]. Group 3: Acquisition Context - In November, Repare announced an agreement to be acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp., with the cash payment per share based on Repare's cash balance at closing [3].

Core Viewpoint - Repare Therapeutics Inc. has entered into a definitive asset purchase agreement with Gilead Sciences, Inc. for the acquisition of its polymerase theta (Pol) ATPase inhibitor, RP-3467, indicating a strategic collaboration in oncology research and development [1] Company Summary - Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on developing innovative cancer therapies [1] - The acquisition of RP-3467 by Gilead is expected to enhance Gilead's oncology portfolio, leveraging its expertise in the field [1] Industry Summary - The oncology research and development sector is witnessing significant consolidation, as companies seek to combine resources and expertise to advance cancer treatment options [1] - The transaction highlights the growing interest in precision oncology and the potential for best-in-class therapies in the market [1]

Core Insights - Class Action Attorney Juan Monteverde's firm has successfully recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] Group 1: Repare Therapeutics Inc. - Repare Therapeutics Inc. is being investigated regarding its sale to XenoTherapeutics, Inc. [1] - Upon closing, each Repare shareholder is expected to receive a cash payment of $1.82 per share, along with a non-transferable contingent value right for additional cash payments under certain conditions [1] Group 2: CNB Bank Shares, Inc. - CNB Bank Shares, Inc. is involved in a sale to HBT Financial, Inc. [2] - CNB shareholders will receive either 1.0434 shares of HBT common stock, $27.73 in cash per share, or a combination of both upon completion of the transaction [2] Group 3: Kimberly-Clark Corporation - Kimberly-Clark Corporation is merging with Kenvue Inc. [3] - Post-merger, Kimberly-Clark shareholders are expected to own approximately 54% of the combined company [3] Group 4: Kenvue Inc. - Kenvue Inc. is being sold to Kimberly-Clark Corporation [4] - Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share [4]